Affinage · Toxoplasma gondii

HDAC3

histone deacetylase HDAC3 · UniProt A0A125YPH4

Annotated
2026-09-08
15 papers in source corpus 13 papers cited in narrative 14 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TgHDAC3 is a class I histone deacetylase in Toxoplasma gondii that acts as the central epigenetic enforcer of developmental-stage identity, maintaining transcriptional repression of stage-specific gene programs in proliferating tachyzoites (PMID:19349466). It is the direct molecular target of the cyclic tetrapeptide inhibitor FR235222, and the Apicomplexa-specific active-site residue T99 is required for this inhibition, defining a druggable catalytic pocket distinct from host HDACs (PMID:19349466). Pharmacological inhibition of TgHDAC3 de-represses roughly 370 genes—a third of them stage-specific—and drives conversion of replicative tachyzoites into non-replicative bradyzoites (PMID:19349466), and independently induces sporozoite-stage genes such as SporoSAG and LEA860 (PMID:39802703). Mechanistically, HDAC3 does not act autonomously but is recruited to promoters of bradyzoite, merozoite, and sexual-stage genes as the effector of a MORC-scaffolded repressor complex, where sequence-specific ApiAP2 transcription factors—including AP2XII-1/AP2XI-2 heterodimers at merozoite loci, AP2XII-2, AP2XII-5, and AP2X-1—target the MORC-HDAC3 module to particular loci to restrict chromatin accessibility (PMID:32094587, PMID:38093015, PMID:39716984, PMID:40823841). This forms a hierarchical ApiAP2 cascade upstream of HDAC3-mediated deacetylation (PMID:38791568), and the MORC/HDAC3 complex acts epistatically upstream of the master bradyzoite regulator BFD1 to control chronic-stage differentiation (PMID:40389644). Disruption of this complex causes chromatin decompaction at target loci and irreversible stage conversion, making the pathway both a driver of parasite persistence and an antiparasitic drug target (PMID:38093015, PMID:40823841).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2007 Low

    Establishing that a Class I HDAC contributes to tachyzoite proliferation was the first step toward identifying a druggable chromatin regulator, addressing whether HDAC activity is required for parasite growth.

    Evidence In vitro anti-parasitic proliferation assays with class-selective HDAC inhibitors and sequence homology in T. gondii RH

    PMID:17626366

    Open questions at the time
    • Class-level inference only, no direct HDAC3 target validation
    • Distinguishes Class I from Class III but not individual HDAC enzymes
    • No mechanistic link to gene regulation
  2. 2009 High

    Identifying TgHDAC3 as the direct target of FR235222 and pinpointing the T99 catalytic residue answered which specific enzyme mediates HDAC inhibitor activity and revealed an Apicomplexa-specific determinant enabling parasite-selective targeting.

    Evidence Drug target identification with active-site mutagenesis of TgHDAC3 T99 and phenotypic rescue in T. gondii

    PMID:19349466

    Open questions at the time
    • Structural basis of T99 selectivity not resolved at atomic level
    • Direct substrate spectrum of HDAC3 not defined
  3. 2009 High

    Linking HDAC3 inhibition to genome-wide transcriptional de-repression and tachyzoite-to-bradyzoite conversion established HDAC3 as a central regulator of stage-specific gene expression rather than merely a growth factor.

    Evidence FR235222 treatment with transcriptome analysis and stage conversion assays in T. gondii

    PMID:19349466

    Open questions at the time
    • Recruitment mechanism to specific promoters unknown at this stage
    • Direct versus indirect targets among the ~370 genes not distinguished
  4. 2010 Medium

    Confirming HDAC3 as the pharmacological target across tachyzoite and bradyzoite/cyst stages and using its structure for rational drug design demonstrated the enzyme's relevance to both acute and chronic infection.

    Evidence Ex vivo cyst treatment, fluorescent labeling, structure-guided medicinal chemistry, and in vivo mouse cyst infection assays

    PMID:20713670

    Open questions at the time
    • No high-resolution experimental structure reported
    • Selectivity over host HDAC3 characterized only pharmacologically
  5. 2020 High

    Discovering that MORC in complex with AP2 factors recruits HDAC3 to sexual-stage promoters resolved how HDAC3 achieves locus specificity, defining it as the enzymatic effector of a sequence-directed repressor complex.

    Evidence Reciprocal Co-IP, chromatin accessibility assays, conditional MORC depletion, and transcriptome analysis in T. gondii

    PMID:32094587

    Open questions at the time
    • Which AP2 factors direct which loci not fully enumerated
    • Order of assembly and role of HDAC3 catalytic activity within the complex not dissected
  6. 2023 High

    Identifying specific ApiAP2 heterodimers (AP2XII-1/AP2XI-2) and additional factors (AP2XII-2) that target the MORC-HDAC3 complex to merozoite and sexual-stage loci established a combinatorial code assigning the repressor complex to distinct developmental gene sets.

    Evidence Conditional depletion, ChIP/CUT&Tag, ATAC-seq, Co-IP, and transcriptome analysis in T. gondii (with corroborating preprint)

    PMID:38093015 PMID:36786611 PMID:36711883

    Open questions at the time
    • Combinatorial rules governing AP2 factor pairing incompletely mapped
    • Contribution of HDAC3 deacetylase activity versus complex scaffolding not separated
  7. 2024 Medium

    Extending the complex to AP2XII-5 (with the novel AIP1) and demonstrating a hierarchical AP2XII-1-led cascade upstream of HDAC3 clarified that multiple ApiAP2 modules feed into a shared MORC-HDAC3 repressive hub.

    Evidence Co-IP/mass spectrometry complex identification, conditional depletion/knockout, and transcriptome/chromatin binding assays in T. gondii

    PMID:39716984 PMID:38791568

    Open questions at the time
    • Functional role of AIP1 within the complex undefined
    • Single-lab complex compositions await independent replication
  8. 2024 Medium

    Showing apicidin inhibition of HDAC3 de-represses sporozoite-specific genes broadened HDAC3's repressive scope to oocyst/sporozoite programs, reinforcing its role as a global gatekeeper of non-tachyzoite gene expression.

    Evidence Apicidin inhibition with immunofluorescence, immunoprecipitation, and mass spectrometry in T. gondii

    PMID:39802703

    Open questions at the time
    • Apicidin selectivity for HDAC3 over other HDACs not fully controlled
    • Direct promoter occupancy at sporozoite genes not shown
  9. 2025 Medium

    Placing the MORC/HDAC3 complex epistatically upstream of BFD1 and identifying AP2X-1 as a further modulator situated HDAC3 within the master bradyzoite differentiation pathway controlling chronic persistence.

    Evidence Genetic epistasis analysis, Co-IP, CUT&Tag, ATAC-seq, conditional knockout, single-cell and bulk transcriptomics in T. gondii

    PMID:40389644 PMID:40823841

    Open questions at the time
    • Molecular mechanism by which HDAC3/MORC represses BFD1 not defined
    • Whether the epistatic relationship is direct or indirect unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • The direct non-histone and histone substrate spectrum of TgHDAC3 and the precise contribution of its catalytic deacetylation versus its scaffolding within the MORC complex to repression remain unresolved.
  • No defined catalog of endogenous acetyl-substrates
  • Catalytic-dead separation-of-function experiments not reported
  • No high-resolution structure of the complete MORC-HDAC3-AP2 assembly

Mechanism profile

Synthesis pass · controlled-vocabulary classification
Partners
AIP1AP2X-1AP2XI-2AP2XII-1AP2XII-2AP2XII-5BFD1 (EPISTATIC DOWNSTREAM REGULATOR)MORC
Complex memberships
AP2XII-5-MORC-HDAC3-AIP1 nuclear repressor complexMORC-HDAC3-AP2 transcriptional repressor complex

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 TgHDAC3 was identified as the direct molecular target of the cyclic tetrapeptide HDACi FR235222 in Toxoplasma tachyzoites; the conserved Apicomplexa-specific residue T99 in TgHDAC3 is critical for the drug's inhibitory activity, established by active-site mutagenesis showing that mutation of T99 abolishes FR235222 inhibition. Drug target identification via genetic/biochemical approach; active-site mutagenesis of TgHDAC3 T99; phenotypic rescue The Journal of experimental medicine High 19349466
2009 Inhibition of TgHDAC3 by FR235222 induces differentiation of tachyzoites (replicative stage) into bradyzoites (non-replicative stage) and influences the expression of approximately 370 genes, a third of which are stage-specifically expressed, establishing TgHDAC3 as a central regulator of gene expression and stage conversion. HDACi treatment (FR235222) followed by transcriptome analysis and stage conversion assays The Journal of experimental medicine High 19349466
2010 FR235222 targets TgHDAC3 in bradyzoites and cyst forms in vitro and ex vivo; structural knowledge of TgHDAC3 was used to rationally design new FR235222 derivative compounds with improved selectivity, confirming HDAC3 as the pharmacological target in both tachyzoite and bradyzoite stages. Ex vivo cyst treatment, fluorescent labeling, structure-guided medicinal chemistry, in vivo cyst infection assay in mice Antimicrobial agents and chemotherapy Medium 20713670
2020 HDAC3 is recruited to chromatin at sexual-stage gene promoters by the MORC protein in complex with AP2 transcription factors, thereby restricting chromatin accessibility and repressing genes exclusively expressed during sexual stages; this positions HDAC3 as an effector within a MORC-AP2 transcriptional repressor complex. Co-immunoprecipitation, chromatin accessibility assays, conditional depletion of MORC, transcriptome analysis Nature microbiology High 32094587
2023 AP2XII-1 and AP2XI-2 bind DNA as heterodimers at merozoite gene promoters in tachyzoites and recruit MORC and HDAC3, thereby limiting chromatin accessibility and repressing merozoite-specific transcription; depletion of both factors causes epigenetic rewiring and tachyzoite-to-merozoite transition. Conditional depletion, ChIP/CUT&Tag, chromatin accessibility (ATAC-seq), Co-immunoprecipitation, transcriptome analysis Nature High 38093015
2023 AP2XII-2 co-occupies genomic loci associated with sexually committed parasites together with HDAC3 and MORC, contributing to the repression of a subset of sexual-stage genes including AP2X-10 and AAH1, as demonstrated by CUT&Tag chromatin profiling and conditional depletion. CUT&Tag, conditional depletion, transcriptome analysis mSphere Medium 36786611
2024 AP2XII-5 forms a nuclear complex with MORC and HDAC3 (as well as the novel protein AIP1) that suppresses developmentally regulated genes at tachyzoite stage; AP2XII-5 binds promoters of developmentally activated genes and recruits MORC and HDAC3 to repress their expression. Immunoprecipitation and mass spectrometry (complex identification), conditional depletion, transcriptome and chromatin binding assays Advanced science (Weinheim, Baden-Wurttemberg, Germany) Medium 39716984
2024 AP2XII-1 and AP2XI-2 target the MORC-HDAC3 complex to merozoite gene promoters; their disruption profoundly alters expression of merozoite-specific genes, with AP2XII-1 specifically binding a subset of ApiAP2 transcription factors including AP2XI-2, establishing a hierarchical ApiAP2 regulatory cascade upstream of HDAC3-mediated repression. Immunoprecipitation, mass spectrometry, conditional knockout, transcriptome analysis International journal of molecular sciences Medium 38791568
2025 MORC and HDAC3 epistatically regulate BFD1 (a key bradyzoite regulator), placing the MORC/HDAC3 repressor complex upstream of BFD1 in the pathway controlling bradyzoite gene expression and chronic persistence. Genetic epistasis analysis, conditional depletion, transcriptome analysis EMBO molecular medicine Medium 40389644
2025 AP2X-1 associates with the HDAC3/MORC complex and co-occupies promoters of bradyzoite- and sexual stage-specific genes; loss of AP2X-1 leads to upregulation of these genes, chromatin decompaction at target loci, and induction of bradyzoite differentiation and sexual commitment, indicating AP2X-1 modulates HDAC3/MORC function to repress developmental gene expression. Co-immunoprecipitation (complex association), CUT&Tag chromatin profiling, ATAC-seq, conditional knockout, transcriptome analysis, single-cell sequencing mBio Medium 40823841
2023 In tachyzoites, AP2XII-1 and AP2XI-2 bind merozoite gene promoters as heterodimers and recruit MORC and HDAC3 to restrict chromatin accessibility; this was confirmed independently in a preprint preceding the published Nature paper. Conditional depletion, CUT&Tag, ATAC-seq, Co-immunoprecipitation bioRxivpreprint Medium 36711883
2024 Pharmacological inhibition of HDAC3 with apicidin (a commercially available HDACi) in tachyzoites induces expression of sporozoite-specific genes including SporoSAG and LEA860, confirming HDAC3 actively represses oocyst/sporozoite-stage gene expression in tachyzoites. Drug inhibition (apicidin), immunofluorescence microscopy, immunoprecipitation, mass spectrometry FEMS microbes Medium 39802703
2007 T. gondii expresses a Class I HDAC enzyme homologous to human HDAC3; hydroxamic acid HDACi compounds (SAHA, scriptaid, TSA) at nanomolar concentrations inhibit tachyzoite proliferation, while the Class III HDAC inhibitor nicotinamide had minimal anti-parasitic activity, functionally implicating Class I HDAC (HDAC3) in tachyzoite replication. In vitro anti-parasitic proliferation assay with selective HDAC inhibitors; sequence homology The Journal of parasitology Low 17626366
2020 Treatment with the HDAC inhibitor Tubastatin A (TST) led to increased histone H4 acetylation and decreased H3 acetylation, impaired endodyogeny (budding of daughter cells), caused centrosome dispersal, apicoplast division defects, mitochondrial membrane potential disruption, and IMC assembly failure; TST possibly inhibits HDAC3 and other HDACs involved in non-histone protein modification. Western blotting (histone acetylation), fluorescence and electron microscopy, mitochondrial membrane potential assay, in vitro proliferation assay International journal for parasitology. Drugs and drug resistance Low 33360687

Source papers

Stage 0 corpus · 15 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. The Journal of experimental medicine 146 19349466
2020 A MORC-driven transcriptional switch controls Toxoplasma developmental trajectories and sexual commitment. Nature microbiology 102 32094587
2023 In vitro production of cat-restricted Toxoplasma pre-sexual stages. Nature 52 38093015
2007 Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. The Journal of parasitology 52 17626366
2010 Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds. Antimicrobial agents and chemotherapy 51 20713670
2023 Toxoplasma gondii AP2XII-2 Contributes to Transcriptional Repression for Sexual Commitment. mSphere 32 36786611
2020 HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics. International journal for parasitology. Drugs and drug resistance 28 33360687
2024 AP2XII-1 and AP2XI-2 Suppress Schizogony Gene Expression in Toxoplasma gondii. International journal of molecular sciences 12 38791568
2024 A Novel Nuclear Protein Complex Controlling the Expression of Developmentally Regulated Genes in Toxoplasma Gondii. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 5 39716984
2023 In vitro production of cat-restricted Toxoplasma pre-sexual stages by epigenetic reprogramming. bioRxiv : the preprint server for biology 5 36711883
2025 Uncovering biomarkers for chronic toxoplasmosis detection highlights alternative pathways shaping parasite dormancy. EMBO molecular medicine 3 40389644
2024 Proteomic identification of a Toxoplasma gondii sporozoite-specific antigen using HDAC3 inhibitor-treated tachyzoites as surrogate. FEMS microbes 2 39802703
2025 Decoding the epigenetic blueprint behind Toxoplasma (pre)sexual commitment and chronic persistence. Current opinion in microbiology 1 40886497
2025 AP2X-1 is a negative regulator of Toxoplasma gondii sexual commitment. mBio 1 40823841
2025 In vitro and in vivo activity of quisinostat against Toxoplasma gondii. Antimicrobial agents and chemotherapy 0 40741955